Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy
NCT ID: NCT06681324
Last Updated: 2025-11-24
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2
Total Enrollment
30 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-12-11
Study Completion Date
2027-06-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to evaluate safety, tolerability, and effect on mucosal repair of AZD7798 compared with placebo in participants with active ileal Crohn's disease and an ileostomy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197
Moderate to Severe Crohn's Disease
RECRUITING
PHASE2
Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease.
NCT06432764
Crohn Disease
ACTIVE_NOT_RECRUITING
PHASE1
A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease
NCT00446433
Crohn's Disease
COMPLETED
PHASE2
Positron Emission Tomography (PET) Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease
NCT06053424
Crohn's Disease
COMPLETED
PHASE1
Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects
NCT01258205
Crohn's Disease
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a participant-and investigator-blind, randomized, parallel-group, placebo controlled phase II study designed to evaluate safety, tolerability, and mucosal repair with AZD7798 in participants with active ileal Crohn's disease and an ileostomy. This study will include a screening period, an induction period, an open-label maintenance period, and a follow-up period. Approximately 30 participants will be randomized globally to receive either AZD7798 or placebo during 12-week participant- and investigator- blind induction period. At week 12 after induction period, all eligible participants will enter 40-week open label maintenance period. Follow-up visits will take place 8 weeks and 18 weeks after the last dose of study intervention, whether this occurs during the induction period or the open-label maintenance period.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Crohn's Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Participants will be randomized 2:1 to receive either AZD7798 or placebo during 12-week participant- and Investigator- blind induction period. At week 12 after induction period, all eligible participants will enter 40-week open label maintenance period.
Primary Study Purpose
OTHER
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AZD7798
AZD7798
Group Type
EXPERIMENTAL
AZD7798
Intervention Type
DRUG
AZD7798
Placebo
Placebo
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
OTHER
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD7798
AZD7798
Intervention Type
DRUG
Placebo
Placebo
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 to 80 years of age.
* Diagnosis of Crohn's disease established with clinical, imaging, endoscopic, and/or histopathologic evidence.
* Ileostomy for at least 3 months.
* Prior to screening endoscopy, clinical suspicion of active ileal inflammation based on at least one of the following: previous endoscopy, imaging (CT, MRI, IUS), or FCP above upper reference limit.
* Active ileal Crohn's disease as determined by active intestinal mucosal inflammation, as demonstrated on video recorded ileoscopy performed during the screening period and scored by a blinded central reader with agreement on the SES CD ≥ 4 of the ileal segment proximal to the stoma. Participants with inflammation in additional intestinal segments are not excluded.
* Capable of giving signed informed consent.
* Diagnosis of Crohn's disease established with clinical, imaging, endoscopic, and/or histopathologic evidence.
* Ileostomy for at least 3 months.
* Prior to screening endoscopy, clinical suspicion of active ileal inflammation based on at least one of the following: previous endoscopy, imaging (CT, MRI, IUS), or FCP above upper reference limit.
* Active ileal Crohn's disease as determined by active intestinal mucosal inflammation, as demonstrated on video recorded ileoscopy performed during the screening period and scored by a blinded central reader with agreement on the SES CD ≥ 4 of the ileal segment proximal to the stoma. Participants with inflammation in additional intestinal segments are not excluded.
* Capable of giving signed informed consent.
Exclusion Criteria
* Concomitant additional gastrointestinal luminal inflammatory diseases
* Strictures/stenoses preventing passage of endoscope throughout the specified segment
* Short bowel syndrome
* Within 3 months prior to screening:
1. Diagnosis of peritonitis or need treatment of peritonitis
2. Bowel perforation or evidence of obstruction
* All intrabdominal, cutaneous and perianal/perirectal abscesses and fistulae are excluded with exception of: cutaneous and perianal/perirectal abscesses which are adequately drained 4 weeks prior to randomization, and intraabdominal fistulae between bowel segments only without complications
* Ongoing or expected nutritional dependency on total enteral or parenteral nutrition during study (partial nutrition acceptable).
* In participants with any remaining colon and/or rectum, evidence of an increased risk of colorectal cancer, including:
1. Adenomatous colonic/rectal polyps that have not been removed
2. Intestinal dysplasia
3. Not undertaking appropriate surveillance, if indicated, for colorectal dysplasia/malignancy
* Reversal of ileostomy or formation of J-pouch planned prior to end of study period.
* High-output stoma (eg, \> 2000 mL/24 hours) associated with volume depletion and/or electrolyte disturbance to the extent that, in the opinion of the Investigator, it may put the participant at undue risk because of participation in the study, or impact their ability to participate in the study or interfere with the interpretation of study data.
* Any of the following treatments within the specified time period:
1. An anti-TNF biologic within 8 weeks prior to randomization
2. Any biologic targeting immune response other than an anti-TNF (including vedolizumab and ustekinumab) within 12 weeks prior to randomization.
3. Other advanced small molecule treatments for Crohn's disease within 4 weeks prior to randomization
4. Cyclosporine, mycophenolate mofetil, sirolimus (rapamycin), thalidomide, or tacrolimus within 4 weeks prior to randomization
5. Treatment with apheresis (eg, Adacolumn, Cellsorba) within 4 weeks prior to randomization
6. Administration of any live vaccine within 4 weeks prior to randomization, or planned administration of any such vaccine during the study
7. Faecal microbiota transplantation within 4 weeks prior to randomization
8. Regular intake of NSAIDs within 12 weeks prior to screening ileoscopy and during the study (defined as at least times per week for more than 3 months; not applicable to daily aspirin use up to 325 mg per day)
9. Lymphocyte-depleting treatment, including, but not limited to rituximab, within 12 months prior to randomization
* Any changes in dosing of the following medications prior to screening ileoscopy as outlined
1. 5-aminosalicylates within 2 weeks
2. Oral corticosteroids within 2 weeks. Also excluded if on stable dosing of steroids exceeding the following dose equivalents:
(i) Systemic steroids \> 20 mg/day prednisolone dose or equivalent (ii) Locally targeted steroids exceeding maximum budesonide dose or equivalent \[9 mg/day\] (c) Immunomodulators (thiopurines or methotrexate) within 4 weeks (d) Antibiotic therapy for the treatment of Crohn's disease, eg, ciprofloxacin or metronidazole within 2 weeks (e) Probiotics within 2 weeks
* Evidence of recent or currently active infection, including use of IV or oral antibiotics for documented infection within 30 days prior to screening.
* Evidence of chronic hepatitis B or C infection
* History of TB (active or latent) unless an appropriate course of treatment has been completed.
* Positive diagnostic TB test at screening.
* History of serious opportunistic infection within 12 months prior to screening
* Symptomatic herpes zoster infection within 3 months prior to screening.
* Positive C. difficile toxin test at screening.
* Any identified immunodeficiency
* Any other abnormal laboratory results at screening, which, in the opinion of the Investigator, will prevent the participant from completing the study or will interfere with the interpretation of the study results
* Prolonged QTcF interval \> 450 ms (or \> 480 ms for patients with bundle branch block) or congenital long-QT syndrome or family history of long-QT syndrome or sudden cardiac death in age \< 40 years.
* Clinically significant cardiovascular conditions
* Reproduction:
1. Pregnant and breastfeeding participants, or those planning to breastfeed during the study
2. FOCBP, unless they agree to complete abstinence or to use a highly effective contraceptive method AND barrier method
* Current malignancy or history of malignancy
* Current significant major or unstable respiratory disease, heart disease, cerebrovascular disease, haematological disease, hepatic disease including large duct primary sclerosing cholangitis with jaundice, recurrent cholangitis or cirrhosis, renal disease, gastrointestinal disease, or other major disease other than active Crohn's disease.
* Current enrolment in another interventional study or treatment with any investigational drug within 4 months (or 5 half-lives, whichever is longer) prior to screening
* Unstable lifestyle factors
* Participants committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
* Involvement in the planning and/or conduct of the study
* Judgement by the Investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
* Previous randomization in the present study.
* Strictures/stenoses preventing passage of endoscope throughout the specified segment
* Short bowel syndrome
* Within 3 months prior to screening:
1. Diagnosis of peritonitis or need treatment of peritonitis
2. Bowel perforation or evidence of obstruction
* All intrabdominal, cutaneous and perianal/perirectal abscesses and fistulae are excluded with exception of: cutaneous and perianal/perirectal abscesses which are adequately drained 4 weeks prior to randomization, and intraabdominal fistulae between bowel segments only without complications
* Ongoing or expected nutritional dependency on total enteral or parenteral nutrition during study (partial nutrition acceptable).
* In participants with any remaining colon and/or rectum, evidence of an increased risk of colorectal cancer, including:
1. Adenomatous colonic/rectal polyps that have not been removed
2. Intestinal dysplasia
3. Not undertaking appropriate surveillance, if indicated, for colorectal dysplasia/malignancy
* Reversal of ileostomy or formation of J-pouch planned prior to end of study period.
* High-output stoma (eg, \> 2000 mL/24 hours) associated with volume depletion and/or electrolyte disturbance to the extent that, in the opinion of the Investigator, it may put the participant at undue risk because of participation in the study, or impact their ability to participate in the study or interfere with the interpretation of study data.
* Any of the following treatments within the specified time period:
1. An anti-TNF biologic within 8 weeks prior to randomization
2. Any biologic targeting immune response other than an anti-TNF (including vedolizumab and ustekinumab) within 12 weeks prior to randomization.
3. Other advanced small molecule treatments for Crohn's disease within 4 weeks prior to randomization
4. Cyclosporine, mycophenolate mofetil, sirolimus (rapamycin), thalidomide, or tacrolimus within 4 weeks prior to randomization
5. Treatment with apheresis (eg, Adacolumn, Cellsorba) within 4 weeks prior to randomization
6. Administration of any live vaccine within 4 weeks prior to randomization, or planned administration of any such vaccine during the study
7. Faecal microbiota transplantation within 4 weeks prior to randomization
8. Regular intake of NSAIDs within 12 weeks prior to screening ileoscopy and during the study (defined as at least times per week for more than 3 months; not applicable to daily aspirin use up to 325 mg per day)
9. Lymphocyte-depleting treatment, including, but not limited to rituximab, within 12 months prior to randomization
* Any changes in dosing of the following medications prior to screening ileoscopy as outlined
1. 5-aminosalicylates within 2 weeks
2. Oral corticosteroids within 2 weeks. Also excluded if on stable dosing of steroids exceeding the following dose equivalents:
(i) Systemic steroids \> 20 mg/day prednisolone dose or equivalent (ii) Locally targeted steroids exceeding maximum budesonide dose or equivalent \[9 mg/day\] (c) Immunomodulators (thiopurines or methotrexate) within 4 weeks (d) Antibiotic therapy for the treatment of Crohn's disease, eg, ciprofloxacin or metronidazole within 2 weeks (e) Probiotics within 2 weeks
* Evidence of recent or currently active infection, including use of IV or oral antibiotics for documented infection within 30 days prior to screening.
* Evidence of chronic hepatitis B or C infection
* History of TB (active or latent) unless an appropriate course of treatment has been completed.
* Positive diagnostic TB test at screening.
* History of serious opportunistic infection within 12 months prior to screening
* Symptomatic herpes zoster infection within 3 months prior to screening.
* Positive C. difficile toxin test at screening.
* Any identified immunodeficiency
* Any other abnormal laboratory results at screening, which, in the opinion of the Investigator, will prevent the participant from completing the study or will interfere with the interpretation of the study results
* Prolonged QTcF interval \> 450 ms (or \> 480 ms for patients with bundle branch block) or congenital long-QT syndrome or family history of long-QT syndrome or sudden cardiac death in age \< 40 years.
* Clinically significant cardiovascular conditions
* Reproduction:
1. Pregnant and breastfeeding participants, or those planning to breastfeed during the study
2. FOCBP, unless they agree to complete abstinence or to use a highly effective contraceptive method AND barrier method
* Current malignancy or history of malignancy
* Current significant major or unstable respiratory disease, heart disease, cerebrovascular disease, haematological disease, hepatic disease including large duct primary sclerosing cholangitis with jaundice, recurrent cholangitis or cirrhosis, renal disease, gastrointestinal disease, or other major disease other than active Crohn's disease.
* Current enrolment in another interventional study or treatment with any investigational drug within 4 months (or 5 half-lives, whichever is longer) prior to screening
* Unstable lifestyle factors
* Participants committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
* Involvement in the planning and/or conduct of the study
* Judgement by the Investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
* Previous randomization in the present study.
Minimum Eligible Age
18 Years
Maximum Eligible Age
80 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Leuven, , Belgium
Site Status
RECRUITING
Research Site
Padua, , Italy
Site Status
RECRUITING
Research Site
Roma, , Italy
Site Status
RECRUITING
Research Site
Rozzano, , Italy
Site Status
RECRUITING
Research Site
Amsterdam, , Netherlands
Site Status
RECRUITING
Research Site
Nijmegen, , Netherlands
Site Status
RECRUITING
Research Site
Lodz, , Poland
Site Status
RECRUITING
Research Site
Poznan, , Poland
Site Status
RECRUITING
Research Site
Poznan, , Poland
Site Status
RECRUITING
Research Site
Warsaw, , Poland
Site Status
RECRUITING
Research Site
Wroclaw, , Poland
Site Status
RECRUITING
Research Site
Gothenburg, , Sweden
Site Status
WITHDRAWN
Research Site
Linköping, , Sweden
Site Status
RECRUITING
Research Site
Stockholm, , Sweden
Site Status
RECRUITING
Research Site
Kyiv, , Ukraine
Site Status
RECRUITING
Research Site
Kyiv, , Ukraine
Site Status
RECRUITING
Research Site
Vinnytsia, , Ukraine
Site Status
RECRUITING
Research Site
Birmingham, , United Kingdom
Site Status
RECRUITING
Research Site
Cambridge, , United Kingdom
Site Status
RECRUITING
Research Site
London, , United Kingdom
Site Status
RECRUITING
Research Site
London, , United Kingdom
Site Status
RECRUITING
Research Site
London, , United Kingdom
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Belgium
Italy
Netherlands
Poland
Sweden
Ukraine
United Kingdom
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D9690C00006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease
NCT01635621
WITHDRAWN
PHASE2
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
NCT02531113
COMPLETED
PHASE2
Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease
NCT00130390
TERMINATED
PHASE2
AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's Disease
NCT05452304
COMPLETED
PHASE1
Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas
NCT00321412
COMPLETED
PHASE3
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease
NCT02249078
WITHDRAWN
PHASE1
Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence.
NCT02247258
TERMINATED
PHASE2
Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease
NCT01203631
COMPLETED
PHASE2
An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
NCT03650413
TERMINATED
PHASE2
A Study of Abatacept in Patients With Active Crohn's Disease
NCT00406653
TERMINATED
PHASE3
Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease
NCT05599347
RECRUITING
PHASE2
Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease
NCT01235689
COMPLETED
PHASE3
Azathioprine Based on Endoscopy After Clinical Remission in Moderate to Severe Ulcerative Colitis
NCT02579733
TERMINATED
PHASE4
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
NCT04173273
TERMINATED
PHASE3
Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon
NCT00348283
COMPLETED
PHASE3
ASTIC Autologous Stem Cell Transplantation for Crohn's Disease
NCT00297193
TERMINATED
PHASE3
Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease
NCT02378688
COMPLETED
PHASE2
A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease
NCT02367183
COMPLETED
PHASE1
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
NCT01751152
COMPLETED
PHASE2
Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
NCT03440385
COMPLETED
PHASE3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy
NCT05470985
TERMINATED
PHASE2/PHASE3
Control Crohn Safe Trial
NCT03917303
RECRUITING
PHASE4
Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease
NCT02048618
COMPLETED
PHASE2
Reduce Risk for Crohn's Disease Patients
NCT02852694
COMPLETED
PHASE4
Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease
NCT04151225
WITHDRAWN
PHASE2